Liad Hinden

1.1k total citations
25 papers, 568 citations indexed

About

Liad Hinden is a scholar working on Surgery, Pharmacology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Liad Hinden has authored 25 papers receiving a total of 568 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 12 papers in Pharmacology and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Liad Hinden's work include Cannabis and Cannabinoid Research (12 papers), Pancreatic function and diabetes (12 papers) and Diet, Metabolism, and Disease (5 papers). Liad Hinden is often cited by papers focused on Cannabis and Cannabinoid Research (12 papers), Pancreatic function and diabetes (12 papers) and Diet, Metabolism, and Disease (5 papers). Liad Hinden collaborates with scholars based in Israel, United States and Switzerland. Liad Hinden's co-authors include Joseph Tam, Adi Drori, Shiran Udi, Alina Nemirovski, Aviram Kogot‐Levin, Reşat Çınar, Saja Baraghithy, Yael Riahi, Rivka Hadar and Gil Leibowitz and has published in prestigious journals such as Nature Communications, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Liad Hinden

23 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liad Hinden Israel 13 220 176 161 138 98 25 568
Delyth Graham United Kingdom 18 64 0.3× 75 0.4× 224 1.4× 232 1.7× 153 1.6× 32 839
Pablo Nakagawa United States 17 62 0.3× 87 0.5× 158 1.0× 307 2.2× 97 1.0× 42 808
Dongjuan Wang China 15 77 0.3× 120 0.7× 133 0.8× 235 1.7× 135 1.4× 32 615
Andrea Delbarba Italy 15 44 0.2× 126 0.7× 273 1.7× 172 1.2× 82 0.8× 23 623
Ming Hao China 15 72 0.3× 130 0.7× 338 2.1× 321 2.3× 58 0.6× 42 812
Chun Xue United States 14 48 0.2× 177 1.0× 246 1.5× 233 1.7× 313 3.2× 21 856
Nicolas Bousette Canada 19 258 1.2× 387 2.2× 119 0.7× 290 2.1× 109 1.1× 30 862
Takuya Kitamura Japan 12 55 0.3× 187 1.1× 45 0.3× 191 1.4× 61 0.6× 25 608
Ann-Maree Duncan Australia 13 130 0.6× 67 0.4× 362 2.2× 275 2.0× 104 1.1× 13 1.0k
Fu-Xian Yi United States 17 83 0.4× 147 0.8× 76 0.5× 203 1.5× 256 2.6× 24 764

Countries citing papers authored by Liad Hinden

Since Specialization
Citations

This map shows the geographic impact of Liad Hinden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liad Hinden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liad Hinden more than expected).

Fields of papers citing papers by Liad Hinden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liad Hinden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liad Hinden. The network helps show where Liad Hinden may publish in the future.

Co-authorship network of co-authors of Liad Hinden

This figure shows the co-authorship network connecting the top 25 collaborators of Liad Hinden. A scholar is included among the top collaborators of Liad Hinden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liad Hinden. Liad Hinden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Madrer, Nimrod, Ofir Israeli, Liad Hinden, et al.. (2025). 5′LysTTT tRNA fragments support survival of botulinum-intoxicated neurons by blocking ferroptosis. 1–17. 1 indexed citations
2.
Wallach‐Dayan, Shulamit B., et al.. (2025). Targeting the endocannabinoid system to suppress mTORC1 hyperactivation in TSC-associated kidney disease. American Journal of Physiology-Renal Physiology. 329(3). F325–F334.
3.
Permyakova, Anna, Saja Baraghithy, Narottam Prasad Sahu, et al.. (2025). Metabolic consequences of altered kidney glucose reabsorption under normoglycemic conditions. Molecular Metabolism. 98. 102192–102192.
4.
Permyakova, Anna, Liad Hinden, Saja Baraghithy, et al.. (2024). Renal Mitochondrial ATP Transporter Ablation Ameliorates Obesity-Induced CKD. Journal of the American Society of Nephrology. 35(3). 281–298. 9 indexed citations
5.
Hinden, Liad, et al.. (2023). Systemic Changes in Endocannabinoids and Endocannabinoid-like Molecules in Response to Partial Nephrectomy-Induced Ischemia in Humans. International Journal of Molecular Sciences. 24(4). 4216–4216. 4 indexed citations
6.
Kogot‐Levin, Aviram, Yael Riahi, Ifat Abramovich, et al.. (2023). Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition. JCI Insight. 8(7). 22 indexed citations
7.
Hinden, Liad, et al.. (2022). Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity. Cannabis and Cannabinoid Research. 8(4). 623–633. 2 indexed citations
8.
Hinden, Liad, Saja Baraghithy, Anna Permyakova, et al.. (2022). Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes. Journal of Controlled Release. 353. 254–269. 10 indexed citations
9.
Hinden, Liad, Alina Nemirovski, Gergő Szanda, et al.. (2022). Opposite physiological and pathological mTORC1-mediated roles of the CB1 receptor in regulating renal tubular function. Nature Communications. 13(1). 1783–1783. 17 indexed citations
10.
Baraghithy, Saja, Liad Hinden, Shiran Udi, et al.. (2021). Renal Proximal Tubule Cell Cannabinoid-1 Receptor Regulates Bone Remodeling and Mass via a Kidney-to-Bone Axis. Cells. 10(2). 414–414. 6 indexed citations
11.
Hinden, Liad, Aviram Kogot‐Levin, Joseph Tam, & Gil Leibowitz. (2021). Pathogenesis of diabesity‐induced kidney disease: role of kidney nutrient sensing. FEBS Journal. 289(4). 901–921. 18 indexed citations
12.
Permyakova, Anna, et al.. (2020). A Novel Indoline Derivative Ameliorates Diabesity-Induced Chronic Kidney Disease by Reducing Metabolic Abnormalities. Frontiers in Endocrinology. 11. 91–91. 8 indexed citations
13.
Drori, Adi, Shahar Azar, Liad Hinden, et al.. (2020). CB1R regulates soluble leptin receptor levels via CHOP, contributing to hepatic leptin resistance. eLife. 9. 18 indexed citations
14.
Kogot‐Levin, Aviram, Liad Hinden, Yael Riahi, et al.. (2020). Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors. Cell Reports. 32(4). 107954–107954. 93 indexed citations
15.
Hinden, Liad, et al.. (2019). Lymphocyte counts may predict a good response to mesenchymal stromal cells therapy in graft versus host disease patients. PLoS ONE. 14(6). e0217572–e0217572. 10 indexed citations
16.
Udi, Shiran, Liad Hinden, Adi Drori, et al.. (2019). Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity‐induced chronic kidney disease. British Journal of Pharmacology. 177(1). 110–127. 52 indexed citations
17.
Hinden, Liad & Joseph Tam. (2019). Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney?. ˜The œNephron journals/Nephron journals. 143(1). 24–27. 14 indexed citations
18.
Tam, Joseph, Liad Hinden, Adi Drori, et al.. (2018). The therapeutic potential of targeting the peripheral endocannabinoid/CB 1 receptor system. European Journal of Internal Medicine. 49. 23–29. 51 indexed citations
19.
Hinden, Liad, Shiran Udi, Adi Drori, et al.. (2017). Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy. Journal of the American Society of Nephrology. 29(2). 434–448. 65 indexed citations
20.
Hinden, Liad, et al.. (2015). Ex Vivo Induced Regulatory Human/Murine Mesenchymal Stem Cells as Immune Modulators. Stem Cells. 33(7). 2256–2267. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Delyth Graham Breakdown of academic impact, for papers by Pablo Nakagawa Breakdown of academic impact, for papers by Dongjuan Wang Breakdown of academic impact, for papers by Andrea Delbarba Breakdown of academic impact, for papers by Ming Hao Breakdown of academic impact, for papers by Chun Xue Breakdown of academic impact, for papers by Nicolas Bousette Breakdown of academic impact, for papers by Takuya Kitamura Breakdown of academic impact, for papers by Ann-Maree Duncan Breakdown of academic impact, for papers by Fu-Xian Yi
Rankless by CCL
2026